Ignite Creation Date:
2025-12-24 @ 2:11 PM
Ignite Modification Date:
2026-01-29 @ 9:54 AM
Study NCT ID:
NCT02433795
Status:
COMPLETED
Last Update Posted:
2021-09-24
First Post:
2015-04-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Sponsor:
Seoul National University Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-05
Start Date Type:
None
Primary Completion Date:
2019-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-10
Completion Date Type:
ACTUAL
First Submit Date:
2015-04-05
First Submit QC Date:
None
Study First Post Date:
2015-05-05
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-09-23
Last Update Post Date:
2021-09-24
Last Update Post Date Type:
ACTUAL